{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P05093",
      "entity_text" : "CYP17A1",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:132971",
      "entity_text" : "Abiraterone",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Abiraterone acetate, designed to inhibit CYP17A1, was approved on November 2011 for treating metastatic CRPC previously treated with docetaxol, with expanded indication approved on December 2012 to include patients who did not receive prior docetaxol.",
  "reading_complete" : "2020-08-04T12:48:35Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T12:47:08Z",
  "trigger" : "inhibit",
  "evidence" : [ "Abiraterone acetate, designed to inhibit CYP17A1" ],
  "pmc_id" : "4209743",
  "score" : 0
}